Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing ...

Shares of Biogen Inc. BIIB slipped 1.28% to $148.82 Friday, on what proved to be an all-around poor trading session for the ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) ("The Company"), today confirmed that Biogen Inc. (Nasdaq: BIIB) ("Biogen") has submitted to the Company an unsolicited, nonbinding proposal to acquire all of ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

This was the stock's second consecutive day of losses.

In a report released today, Mohit Bansal from Wells Fargo assigned a Hold rating to Biogen (BIIB – Research Report), with a price target of ...

Biogen (BIIB) announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Feire reports to Adam ...